NCT07119021RecruitingPhase 4
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
Source: ClinicalTrials.gov · Last updated 12 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 1 Aug 2025
- Start date
- 1 Aug 2024
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Ruijun Ji
- Diseases
- Stroke
- NCT number
- NCT07119021
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 300
- From 1 Aug 2024 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Comorbidity with other serious diseases that affect outcome determination;
- Comorbidity with other serious diseases that affect prognostic regression;
- Comorbidity with other serious diseases with a life expectancy of less than 1 year;
Other
- Pregnant women, women in labor, and patients in the puerperium;
Who the study is looking for
- Age 18-80 years;
- Acute ischemic stroke as defined by the International Health Organization (WHO) and confirmed by cranial CT;
- Onset within a 4.5-hour time window;
- NIHSS score of 6-24;
- Meet the criteria for intravenous thrombolysis in acute ischemic stroke recommended by international guidelines;
- Patient or family consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital of Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.